Company news

Fulcrum Therapeutics, Inc. news in 2026

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

August 17, 2026

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

June 1, 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

April 27, 2026

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

April 27, 2026

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8: 00 a.m. ET

April 20, 2026

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

March 19, 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

February 24, 2026

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 23, 2026

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 17, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2026

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026